feedback

Activity Details

Free CME
1.5 AMA PRA Category 1 Credit(s)
Released: June 25, 2020
Expires: June 25, 2021
90 minutes to complete

Accredited By

Target Audience

This educational initiative has been designed for pulmonologists, rheumatologists, and internal medicine physicians involved in the care of patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD).

Learning Objectives

  • Implement best practice recommendations for ILD screening and assessment of risk for progressive ILD in patients with SSc
  • Outline a tailored approach to SSc-ILD treatment that is consistent with current clinical trial evidence of new regimens
  • Utilize communication strategies that facilitate accurate symptom reporting, improve disease understanding, and promote treatment adherence among patients with SSc-ILD

Activity Description

ILD is associated with early mortality and is the most frequent cause of death among individuals with SSc. Over the past several years, there has been a dramatic increase in awareness of the risk for SSc-ILD, and the need for early diagnosis and treatment to improve health outcomes. Nevertheless, accomplishment of this goal remains difficult for several reasons, including the significant challenge associated with accurately identifying patients at risk for rapidly progressive disease. While a number of risk factors have been previously identified, there are currently no formal guidelines for evaluation and staging. Outcome improvements have been hindered for years due to the lack of approved therapies for SSc-ILD. Change may now be possible with the recent approval of nintedanib for SSc-ILD, the only FDA-approved medicine that slows the rate of decline in pulmonary function. This advance in treatment coupled with the progress of emerging therapies that have shown promise in their capacity to slow, and potentially halt, the progression of fibrosis in SSc-ILD give new hope to clinicians and patients. With this in mind, this program has been designed to provide clinicians with guidance on the integration of new and emerging agents, in addition to the knowledge and skills required to provide patients with SSc-ILD with early diagnosis and optimal disease management.

Faculty

Kristin Highland, MD
Director, Rheumatic Lung Disease Program
Cleveland Clinic
Cleveland, Ohio


Steven D. Nathan, MD
Medical Director, Lung Transplant Program
Director, Advanced Lung Disease Program
Co-director, Inova Pulmonary Hypertension Program
Inova Fairfax Hospital
Fairfax, Virginia

Conflict of Interest Policy/Disclosure Statement

Integrity Continuing Education, Inc. requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The following faculty/planners reported the financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of these CME activities:

Kristin Highland, MD
Consulting Fees: Actelion Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals, Inc., United Therapeutics
Speakers’ Bureaus: Actelion Pharmaceuticals, Bayer Healthcare, Boehringer Ingelheim Pharmaceuticals, Inc., Gilead Sciences, United Therapeutics
Contracted Research: Actelion Pharmaceuticals, Bayer Healthcare, Boehringer Ingelheim Pharmaceuticals, Inc., Eiger Pharmaceuticals, Genentech, Gossamer Bio, Reata Pharmaceuticals, United Therapeutics

Steven D. Nathan, MD
Consulting Fees: Boehringer Ingelheim Pharmaceuticals, Inc., Galapagos, Roche-Genentech
Speakers’ Bureaus: Boehringer Ingelheim Pharmaceuticals, Inc., Roche-Genentech

The Integrity Continuing Education, Inc. planners and managers have nothing to disclose.

Accreditation Statement

Integrity Continuing Education, Inc. is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Integrity Continuing Education, Inc. designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credit(s). Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

There are no fees for participating and receiving CME credit for this activity. During the period of June 25, 2020 through June 25, 2021 participants must:

  • Read the learning objectives and faculty disclosures
  • Complete the pretest
  • Study the educational activity
  • Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 70% or better.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. does not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

The information provided in this CME activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

Contact Information for Questions About the Activity

For information about the ACCME accreditation of this activity, please contact Integrity Continuing Education, Inc. at (855) 835-4004 or via email at information@integrityce.com.

Statement of Commercial Support

This activity is supported by an independent educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.

Suggest a CME Activity

Please provide below the URL and description of an activity you would like to add to OpenCME. You are welcome to add activities as often as you like. To prevent spam or other abuse, activities are reviewed by our editorial team before appearing on OpenCME.

OpenCME for Publishers

Please use the form below if you would like to offer your website visitors high-quality CME content by adding the OpenCME Widget to one or more of your pages.

Start Activity

Select your specialty

You must select a specialty

Send Email to a Colleague

To share this activity with one or more colleagues, enter their e-mail addresses below. To include a personal message, simply overwrite the suggested text below.

(So your recipient knows it's from you.)
Enter multiple recipients separated by a space.
Optionally, replace/modify in the box above the message that will be sent to your colleague(s) with a link to download this app.